Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Merit snaps up Thomas Medical. Halma buys MicroSurgical Technology. Sanofi settles Hyalgan charges. More news briefs.

You may also be interested in...



People Briefs: InVivo Therapeutics CEO Resigns; CVPath Institute, Harvard Bioscience Appoint New CEOs

InVivo Therapeutics Holdings Corp. chairman and CEO resigns. CVPath Institute and Harvard Bioscience get new CEOs. Cook Medical appoints VP to lead its aortic intervention clinical division. Sunshine Heart names chief medical officer.

News In Brief

News from a California biomed survey, Orthofix sentencing and more.

News In Brief

GE Healthcare buys U-Systems for breast ultrasound device. Bausch & Lomb snaps up Technolas Perfect Vision. Orthofix settles Blackstone kickbacks case. More news briefs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031841

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel